Volume : 10, Issue : 02, February – 2023
Title:
22.AN OVERVIEW OF MANAGEMENT APPROACH TO PAIN CRISIS IN SICKLE CELL DISEASE PATIENT
Authors :
Dr/ Eyad Aqeel Mutwalli, Safar othman alzahrani, Bahaa Abdulatief Milibari, Nabeel fawzi shaikh, OTHMAN YAGOOB BARNAWI, Faisal Awad Alzahrani, Mashhour Saleem Bondagji, Mukhled Odis Alqurashi, Abdullah Ahmed Alharbi, Ahmad Hamza Almaghamsi
Abstract :
Sickle cell disease (SCD) is a hereditary illness characterized by hemolytic anemia, end-organ damage, diminished survival, and discomfort. A literature search was conducted using PubMed, CINAHL, and Embase. Databases were searched for all relevant studies to our topic published up to the beginning of 2022. Recurrent and unpredictable episodes of intense pain due to vasoocclusive crisis requiring hospitalization are one of the distinctive characteristics of SCD. In addition, SCD patients frequently have chronic persistent pain. Presently, opioids are used to treat sickle cell anguish, a method that is limited by unwanted effects. Because pain can begin in infancy and persist throughout life, preventing its onset may be preferable to treating it once it has been triggered.
Cite This Article:
Please cite this article in press Eyad Aqeel Mutwalli et al, An Overview Of Management Approach To Pain Crisis In Sickle Cell Disease Patient., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
1. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178(4537):792–794.
2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647–3656.
3. Ballas SK. Sickle Cell Pain (ed 2nd edition). Washington, D.C., USA: IASP Press; 2014.
4. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–323.
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644.
6. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750–760.
7. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
8. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129(20):2719–2726.
9. Gupta M, Msambichaka L, Ballas SK, Gupta K. Morphine for the treatment of pain in sickle cell disease. ScientificWorldJournal. 2015;2015:540154.
10. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529–10533, 2003.
11. Jacob E, Chan VW, Hodge C, Zeltzer L, Zurakowski D, Sethna NF. Sensory and thermal quantitative testing in children with sickle cell disease. J Pediatr Hematol Oncol 37: 185–189, 2015.
12. Khaibullina A, Almeida LE, Wang L, Kamimura S, Wong EC, Nouraie M, Maric I, Albani S, Finkel J, Quezado ZM. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells Mol Dis 55: 363–372, 2015.
13. Klein LM, Lavker RM, Matis WL, Murphy GF. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA 86: 8972–8976, 1989.
14. Gupta K, Jahagirdar O, Gupta K. Targeting pain at its source in sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2018 Jul 1;315(1):R104-R112.
15. Rosenstiel AK, Keefe F. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983;17:33–44.
16. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis. 2019;14(1):421058352.
17. Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017;130(22):2377–85.
18. Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell dis- ease pain. J Pain. 2017;18(5):490–8.
19. Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, et al. Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv. 2018;2(18):2412–7.
20. Cacciotti C, Vaiselbuh S, Romanos-Sirakis E. Pain management for sickle cell disease in the pediatric emergency department: medica- tions and hospitalization trends. Clin Pediatr. 2017;56:1109–14.
21. Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, Citero V, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project. J Opioid Manag. 2015;11(3):243–53.
22. Vincent L, Vang D, Nguyen J, Gupta M, Luk K, Ericson ME, Simone DA, Gupta K. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood 122: 1853–1862, 2013. doi: 10.1182/blood-2013-04-498105.
23. Wu Z, Chen X, Liu F, Chen W, Wu P, Wieschhaus AJ, Chishti AH, Roche PA, Chen WM, Lin TJ. Calpain-1 contributes to IgE-mediated mast cell activation. J Immunol 192: 5130–5139, 2014. doi: 10.4049/jimmunol.1301677.
24. Thakur AS, Littaru GP, Moesgaard S, Dan Sindberg C, Khan Y, Singh CM. Hematological parameters and RBC TBARS level of Q 10 supplemented tribal sickle cell patients: a hospital based study. Indian J Clin Biochem 28: 185–188, 2013.
25. Uhelski ML, Gupta K, Simone DA. Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. Pain 158: 1711–1722, 2017.
26. Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol 177: 620–629, 2017.
27. Desroches J, Bouchard JF, Gendron L, Beaulieu P. Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 261: 23–42, 2014.
28. Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J Haematol 131: 123–128, 2005.
29. Darbari DS, Hampson JP, Ichesco E, Kadom N, Vezina G, Evangelou I, Clauw DJ, Taylor Vi JG, Harris RE. Frequency of hospitalizations for pain and association with altered brain network connectivity in sickle cell disease. J Pain 16: 1077–1086, 2015.
30. DeBaun MR, Schatz J, Siegel MJ, Koby M, Craft S, Resar L, Chu JY, Launius G, Dadash-Zadeh M, Lee RB, Noetzel M. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 50: 1678–1682, 1998.
31. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24: 788–798, 2010.
32. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 168: 960–976, 2017. [Erratum in Cell 169: 361–371, 2017.
33. Gaudre N, Cougoul P, Bartolucci P, Dörr G, Bura-Riviere A, Kamar N, Del Bello A. Improved fetal hemoglobin with mTOR inhibitor-based immunosuppression in a kidney transplant recipient with sickle cell disease. Am J Transplant 17: 2212–2214, 2017.
2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647–3656.
3. Ballas SK. Sickle Cell Pain (ed 2nd edition). Washington, D.C., USA: IASP Press; 2014.
4. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–323.
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644.
6. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750–760.
7. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
8. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129(20):2719–2726.
9. Gupta M, Msambichaka L, Ballas SK, Gupta K. Morphine for the treatment of pain in sickle cell disease. ScientificWorldJournal. 2015;2015:540154.
10. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529–10533, 2003.
11. Jacob E, Chan VW, Hodge C, Zeltzer L, Zurakowski D, Sethna NF. Sensory and thermal quantitative testing in children with sickle cell disease. J Pediatr Hematol Oncol 37: 185–189, 2015.
12. Khaibullina A, Almeida LE, Wang L, Kamimura S, Wong EC, Nouraie M, Maric I, Albani S, Finkel J, Quezado ZM. Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells Mol Dis 55: 363–372, 2015.
13. Klein LM, Lavker RM, Matis WL, Murphy GF. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA 86: 8972–8976, 1989.
14. Gupta K, Jahagirdar O, Gupta K. Targeting pain at its source in sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2018 Jul 1;315(1):R104-R112.
15. Rosenstiel AK, Keefe F. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983;17:33–44.
16. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis. 2019;14(1):421058352.
17. Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017;130(22):2377–85.
18. Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell dis- ease pain. J Pain. 2017;18(5):490–8.
19. Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, et al. Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv. 2018;2(18):2412–7.
20. Cacciotti C, Vaiselbuh S, Romanos-Sirakis E. Pain management for sickle cell disease in the pediatric emergency department: medica- tions and hospitalization trends. Clin Pediatr. 2017;56:1109–14.
21. Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, Citero V, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project. J Opioid Manag. 2015;11(3):243–53.
22. Vincent L, Vang D, Nguyen J, Gupta M, Luk K, Ericson ME, Simone DA, Gupta K. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood 122: 1853–1862, 2013. doi: 10.1182/blood-2013-04-498105.
23. Wu Z, Chen X, Liu F, Chen W, Wu P, Wieschhaus AJ, Chishti AH, Roche PA, Chen WM, Lin TJ. Calpain-1 contributes to IgE-mediated mast cell activation. J Immunol 192: 5130–5139, 2014. doi: 10.4049/jimmunol.1301677.
24. Thakur AS, Littaru GP, Moesgaard S, Dan Sindberg C, Khan Y, Singh CM. Hematological parameters and RBC TBARS level of Q 10 supplemented tribal sickle cell patients: a hospital based study. Indian J Clin Biochem 28: 185–188, 2013.
25. Uhelski ML, Gupta K, Simone DA. Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. Pain 158: 1711–1722, 2017.
26. Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol 177: 620–629, 2017.
27. Desroches J, Bouchard JF, Gendron L, Beaulieu P. Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 261: 23–42, 2014.
28. Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J Haematol 131: 123–128, 2005.
29. Darbari DS, Hampson JP, Ichesco E, Kadom N, Vezina G, Evangelou I, Clauw DJ, Taylor Vi JG, Harris RE. Frequency of hospitalizations for pain and association with altered brain network connectivity in sickle cell disease. J Pain 16: 1077–1086, 2015.
30. DeBaun MR, Schatz J, Siegel MJ, Koby M, Craft S, Resar L, Chu JY, Launius G, Dadash-Zadeh M, Lee RB, Noetzel M. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 50: 1678–1682, 1998.
31. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24: 788–798, 2010.
32. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 168: 960–976, 2017. [Erratum in Cell 169: 361–371, 2017.
33. Gaudre N, Cougoul P, Bartolucci P, Dörr G, Bura-Riviere A, Kamar N, Del Bello A. Improved fetal hemoglobin with mTOR inhibitor-based immunosuppression in a kidney transplant recipient with sickle cell disease. Am J Transplant 17: 2212–2214, 2017.